Kaput Acquisitions, Cancer Drugs and Quality Measures
It seems likely that Anthem’s plan to buy Cigna will not be approved, since it would substantially reduce competition in many metropolitan areas.
Reuters reports that the price of some off-patent cancer drugs have been facing steep price increases in recent years.
In this article from Common Health, industry leaders note that new treatments come with a price tag that many believe is unsustainable.
National Pharmaceutical Council reports on a new study published in the Journal of Managed Care & Specialty Pharmacy.
European prices for some off-patent cancer drugs have risen by more than 100 percent in the past five years, with two cases of hikes exceeding 1,000 percent.